We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current EYE market cap is 24.6M. The company's latest EPS is AUD -0.0384 and P/E is -2.86.
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 82.07M | 13.62M | 14.91M | 17.66M | 23.84M |
| Operating Income | -2.53M | -4.94M | -8.42M | -11.36M | -8.46M |
| Net Income | 35.65M | -4.36M | -7.5M | -15.29M | -8.79M |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 116.74M | 41.99M | 36.63M | 30.36M | 29.88M |
| Total Liabilities | 16.16M | 6.66M | 6.23M | 7.17M | 8.55M |
| Total Equity | 100.59M | 35.34M | 30.4M | 23.19M | 21.33M |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | 5.4M | -13.14M | -4.72M | -6.82M | -7.86M |
| Investing | 88.31M | -2.98M | -4.54M | -697k | -325k |
| Financing | -13.29M | -61.61M | -402k | 6.82M | 6.91M |
| Market Cap | 24.6M |
| Price to Earnings Ratio | -2.86 |
| Price to Sales Ratio | 1.06 |
| Price to Cash Ratio | 4.09 |
| Price to Book Ratio | 1.18 |
| Dividend Yield | - |
| Shares Outstanding | 228.8M |
| Average Volume (1 week) | 1.54M |
| Average Volume (1 Month) | 1.05M |
| 52 Week Change | -48.81% |
| 52 Week High | 0.30 |
| 52 Week Low | 0.105 |
| Spread (Intraday) | 0.01 (4.55%) |
| Company Name | Nova Eye Medical Limited |
| Address |
107 rundle st adelaide, south australia 5067 |
| Website | https://www.nova-eye.com |
| Industry | health care diversified (H) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
